Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,434 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Targeting GOF p53 and c-MYC through LZK Inhibition or Degradation Suppresses Head and Neck Tumor Growth.
Funk AL, Katerji M, Afifi M, Nyswaner K, Woodroofe CC, Edwards ZC, Lindberg E, Bergman KL, Gough NR, Rubin MR, Karpińska K, Trotter EW, Dash S, Ries AL, James A, Robinson CM, Difilippantonio S, Karim BO, Chang TC, Chen L, Xu X, Doroshow JH, Ahel I, Marusiak AA, Swenson RE, Cappell SD, Brognard J. Funk AL, et al. Among authors: james a. bioRxiv [Preprint]. 2024 Nov 20:2024.11.19.623840. doi: 10.1101/2024.11.19.623840. bioRxiv. 2024. PMID: 39605563 Free PMC article. Preprint.
Targeting NAD+ Metabolism Vulnerability in FH-Deficient Hereditary Leiomyomatosis and Renal Cell Carcinoma with the novel NAMPT Inhibitor OT-82.
Najera SS, Ricketts CJ, Schmidt LS, Medina JI, Saito K, Ileva L, Brender JR, James AM, Peer CJ, Gouker B, Karim BO, Chernova O, Wells C, Wei MH, Yang Y, Zhang X, Klumpp-Thomas C, Travers J, Chen L, Wilson KM, Issaq SH, Figg WD, Difilippantonio S, Kalen JD, Krishna MC, Thomas CJ, Ceribelli M, Heske CM, Crooks DR, Meier JL. Najera SS, et al. Mol Cancer Ther. 2024 Oct 14. doi: 10.1158/1535-7163.MCT-24-0225. Online ahead of print. Mol Cancer Ther. 2024. PMID: 39397296
3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) Positron Emission Tomography as an In Vivo Biomarker of inhibition of CDK 4/6-Rb pathway by Palbociclib in a patient derived bladder tumor.
Tatum JL, Kalen JD, Jacobs PM, Riffle LA, James A, Thang L, Sanders C, Hollingshead MG, Basuli F, Shi J, Doroshow JH. Tatum JL, et al. Among authors: james a. J Transl Med. 2022 Aug 18;20(1):375. doi: 10.1186/s12967-022-03580-8. J Transl Med. 2022. PMID: 35982453 Free PMC article.
Toward a CRISPR-based mouse model of Vhl-deficient clear cell kidney cancer: Initial experience and lessons learned.
Stransky LA, Gao W, Schmidt LS, Bi K, Ricketts CJ, Ramesh V, James A, Difilippantonio S, Ileva L, Kalen JD, Karim B, Jeon A, Morgan T, Warner AC, Turan S, Unite J, Tran B, Choudhari S, Zhao Y, Linn DE, Yun C, Dhandapani S, Parab V, Pinheiro EM, Morris N, He L, Vigeant SM, Pignon JC, Sticco-Ivins M, Signoretti S, Van Allen EM, Linehan WM, Kaelin WG Jr. Stransky LA, et al. Among authors: james a. Proc Natl Acad Sci U S A. 2024 Oct 8;121(41):e2408549121. doi: 10.1073/pnas.2408549121. Epub 2024 Oct 4. Proc Natl Acad Sci U S A. 2024. PMID: 39365820 Free PMC article.
Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.
Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y. Marzi L, et al. Among authors: james a. Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10. Mol Cancer Ther. 2018. PMID: 29748210 Free PMC article.
High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma.
Lang M, Schmidt LS, Wilson KM, Ricketts CJ, Sourbier C, Vocke CD, Wei D, Crooks DR, Yang Y, Gibbs BK, Zhang X, Klumpp-Thomas C, Chen L, Guha R, Ferrer M, McKnight C, Itkin Z, Wangsa D, Wangsa D, James A, Difilippantonio S, Karim B, Morís F, Ried T, Merino MJ, Srinivasan R, Thomas CJ, Linehan WM. Lang M, et al. Among authors: james a. J Exp Clin Cancer Res. 2023 Apr 25;42(1):99. doi: 10.1186/s13046-023-02667-4. J Exp Clin Cancer Res. 2023. PMID: 37095531 Free PMC article.
Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma.
Stauffer S, Roth JS, Hernandez ER, Kowalczyk JT, Sealover NE, Hebron KE, James A, Isanogle KA, Riffle LA, Ileva L, Luo X, Chen JQ, Kedei N, Kortum RL, Lei H, Shern JF, Kalen JD, Edmondson EF, Hall MD, Difilippantonio S, Thiele CJ, Yohe ME. Stauffer S, et al. Among authors: james a. Cancers (Basel). 2024 Jun 25;16(13):2320. doi: 10.3390/cancers16132320. Cancers (Basel). 2024. PMID: 39001383 Free PMC article.
4,434 results